Literature DB >> 8164026

Effects of topical tretinoin on dysplastic nevi.

A C Halpern1, L M Schuchter, D E Elder, D Guerry, R Elenitsas, B Trock, I Matozzo.   

Abstract

PURPOSE: As potential precursors of melanoma and markers of increased melanoma risk, dysplastic nevi are suitable targets of strategies for melanoma chemoprevention. We report the results of a pilot study of topical retinoic acid in patients with dysplastic nevi. PATIENTS AND METHODS: Five male patients with dysplastic nevi applied tretinoin to half of the back for 6 months. Baseline photographs of dysplastic nevi were compared with posttreatment photographs and assessed for morphologic change. At study completion, each subject had four nevi excised from the treated side and four from the untreated side of the back. Biopsies were histologically evaluated for the presence of dysplasia.
RESULTS: All patients developed signs of irritation as a result of treatment. One patient was not compliant with treatment due to skin irritation. The four compliant patients showed significant decreases in the clinical atypia of treated lesions, with concomitant fading and even disappearance of many treated nevi. Histologically, only four of 16 treated nevi met histologic criteria for dysplasia, in comparison to 13 of 16 untreated nevi.
CONCLUSION: These results suggest that there is concomitant clinical and histologic improvement in a significant percentage of dysplastic nevi treated with topical tretinoin. However, the utility of topical tretinoin for chemoprevention of melanoma is limited by difficulty of application and associated inflammation. While new strategies in chemoprevention of melanoma are explored, sun protection and assiduous avoidance of sunburn must remain the mainstay of melanoma prevention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8164026     DOI: 10.1200/JCO.1994.12.5.1028

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  5 in total

1.  Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model.

Authors:  Christopher D Lao; Timothy Johnson; Vernon K Sondak; Lori Lowe; David S L Kim; Lili Zhao; Mark Naftanel; Stephen Olsen; Dean E Brenner
Journal:  J Am Acad Dermatol       Date:  2011-06       Impact factor: 11.527

2.  Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.

Authors:  Clara Curiel-Lewandrowski; Susan M Swetter; Janine G Einspahr; Chiu-Hsieh Hsu; Ray Nagle; Paul Sagerman; Joseph Tangrea; Howard Parnes; David S Alberts; Hsiao-Hui Chow
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 3.  Current and emerging technologies in melanoma diagnosis: the state of the art.

Authors:  Estee L Psaty; Allan C Halpern
Journal:  Clin Dermatol       Date:  2009 Jan-Feb       Impact factor: 3.541

Review 4.  Tretinoin. A review of its pharmacological properties and clinical efficacy in the topical treatment of photodamaged skin.

Authors:  S Noble; A J Wagstaff
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

Review 5.  Retinoids: present role and future potential.

Authors:  T R Evans; S B Kaye
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.